Retigabine

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 149-154

  Porter, Roger J ^a   Nohria, Virinder ^b   Rundfeldt, Chris ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b elbion AG ^*  (United States)

^c Elbion AG   (Germany)

Author keywords

epilepsy; partial onset seizures; potassium channels; Retigabine

Indexed keywords

ANTICONVULSIVE AGENT; BICUCULLINE; CARBAMAZEPINE; ETHOSUXIMIDE; FLUPIRTINE; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; PENICILLIN G; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; PLACEBO; POTASSIUM CHANNEL; RETIGABINE; STRYCHNINE; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HEARING LOSS; HUMAN; IN VITRO STUDY; IRRITABLE COLON; KINDLING; MONOTHERAPY; NERVE CELL EXCITABILITY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEIZURE; TINNITUS; TREATMENT DURATION; URINE INCONTINENCE;

ANIMALS; ANTICONVULSANTS; BRAIN; CARBAMATES; CLINICAL TRIALS; EPILEPSY; HUMANS; PHENYLENEDIAMINES;

EID: 33846188558     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.11.012     Document Type: Article

References (36)

1. Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342 (1998) 1-13
2. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14 (1993) 325-331
3. Kupferberg H.J. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 30 suppl 1 (1989) S51-S56
4. Jakovlev V., Achterrath-Tuckermann U., von Schlichtegroll A., Stroman F., and Thiemer K. General pharmacologic studies on the analgesic flupirtine. [In German]. Arzneimittelforschung 35 (1985) 44-55
5. Seaman C.A., Sheridan P.H., Engel J., Molliere M., Narang P.K., and Nice F.J. Flupirtine. In: Meldrum B.S., and Porter R.J. (Eds). New anticonvulsant drugs. Current Problems in Epilepsy 4 (1986), Libbey, London 135-146
6. Seydel J.K., Schaper K.J., Coats E.A., et al. Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines. J Med Chem 37 (1994) 3016-3022
7. Rostock A., Tober C., Rundfeldt C., et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23 (1996) 211-223
8. Tober C., Rundfeldt C., Rostock A., and Bartsch R. The phenyl carbamic acid ester D-23129 is highly effective against amygdale kindled seizures in rats. Eur J Pharmacol 7 suppl (1994) 212 Abstract
9. Löscher W., and Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res 17 (1994) 95-134 Review
10. Nickel B., Shandra A., Godlevsky L., Mazarati A., Kupferberg H., and Szelenyi I. Anticonvulsant activity of D-20443. Naunyn Schmiedebergs Arch Pharmacol 347 suppl (1993) R142 Abstract
11. Nickel B., Shandra A., Godlevsky L., Mazarati A., Kupferberg H., and Szelenyi I. Antiepileptic activity of a new drug: D-20443. Epilepsia 34 suppl 1 (1993) 95 Abstract
12. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs?. A proposal based on experimental and clinical considerations. Epilepsy Res 2 (1988) 145-181
13. Dailey J.W., Cheong J.H., Ko K.H., Adams-Curtis L.E., and Jobe P.C. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci Lett 195 (1995) 77-80
14. Tober C., Rundfeldt C., Rostock A., and Bartsch R. The phenyl carbamic acid ester D-23129 is highly effective in epilepsy models for generalized and focal seizures at nontoxic doses. Abstr Soc Neurosci 20 (1994) 1641 Abstract
15. Tober C., Rostock A., Rundfeldt C., and Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303 (1996) 163-169
16. Engel J. Clinical aspects of epilepsy. Epilepsy Res 10 (1991) 9-17
17. Ganguly A., Wolf H.H., and White H.S. Investigational anticonvulsant D-23129 inhibits limbic behavioral seizures in hippocampal kindled rats. Epilepsia 36 suppl 4 (1995) 49 Abstract
18. Armand V., Rundfeldt C., and Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 41 (2000) 28-33
19. Armand V., Rundfeldt C., and Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 33-39
20. Straub H., Kohling R., Hohling J., et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 44 (2001) 155-165
21. Tober C. Investigations of the effects of retigabine in the amygdala kindling model in rats (1997), University of Leipzig, Leipzig, Germany [dissertation]
22. Rundfeldt C., and Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 282 (2000) 73-76
23. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 336 (1997) 243-249
24. Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res 35 (1999) 99-107
25. Rundfeldt C., and Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50 (2000) 1063-1070
26. Biervert C., Schroeder B.C., Kubisch C., et al. A potassium channel mutation in neonatal human epilepsy. Science 279 (1998) 403-406
27. + channels causes epilepsy. Nature 396 (1998) 687-690
28. Gribkoff V.K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7 (2003) 737-748
29. Blackburn-Munro G., and Jensen B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 460 (2003) 109-116
30. Dost R., Rostock A., and Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 382-390
31. Ebert U., Brandt C., and Löscher W. Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia 43 suppl 5 (2002) 86-95
32. Argentieri TM, Sheldon JH, Bowlby MR, inventors; American Home Products Corporation, assignee. Methods for modulating bladder function. US patent 6 348 486. Feb. 19, 2002.
33. Burbridge S.A., Clare J.J., Cox B., Dupere J., Hagan R.M., and Xie X. New uses for potassium channel openers. WO Patent WO1407768 (2001) January 11
34. Kharkovets T., Hardelin J.P., Safieddine S., et al. KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A 97 (2000) 4333-4338
35. Sachdeo R.C., Ferron G.M., Partiot A.M., et al. An early determination of drug-drug interactions between valproic acid, phenytoin, carbamazepine, or topiramate and retigabine in epileptic patients. Neurology 56 (2001) A331-A332 Abstract
36. Porter R, Alves W, Nohria V; on behalf of the 2005 study group. Poster abstract 01175 [CD-ROM]. 2005 World Congress of Neurology, 5-11 Nov. 2005, Sydney, Australia. J Neurol Sci 2005;15(suppl 1):S1-S526.